Celanese Corp (CE) · Nov 2, 2026 · Earnings

Celanese earnings beat EPS, but revenue misses and cash flow rises

Beat — adj. EPS $1.65 vs ~$1.56 consensus

Celanese earnings beat EPS expectations and raised 2026 free-cash-flow guidance, but weak volumes left revenue below consensus.

Celanese is executing a debt-heavy turnaround: shifting toward higher-margin medical, electronics, and downstream materials while using cost cuts, divestitures, and cash generation to reduce leverage. This quarter advances that plan, but the operating recovery is still uneven.

The earnings beat came with a revenue-quality caveat. Adjusted EPS of $1.65 exceeded the published consensus of roughly $1.56, but $2.556 billion of revenue was below the roughly $2.62 billion consensus. Revenue rose 6% year over year because pricing more than offset a 4% volume decline; the headline earnings result therefore reflects mix, pricing, and productivity more than broad-based demand growth. The company said, “Today, we reported third quarter 2026 adjusted earnings per share of $1.65,” while the financial tables show Q3 revenue of $2,556 million versus $2,419 million a year earlier. 〔0〕

MetricQ3 2026Q3 2025Consensus
Adjusted EPS (Prepared remarks)$1.65 (+23%)$1.34~$1.56
Revenue (Table 4b)$2,556M (+6%)$2,419M~$2,620M
Adjusted EBIT (Table 1)$367M (+13%)$326M
Free cash flow (Cash flow table)$461M (+23%)$375M
Net debt (Balance sheet table)$10,183M (-11%)$11,414M

Cash conversion is the clearest positive change. Third-quarter free cash flow reached $461 million, helped by a $184 million working-capital inflow, and management raised full-year 2026 free-cash-flow guidance to $750 million–$800 million. That directly supports the deleveraging story: net debt fell to $10.2 billion from $11.4 billion a year earlier, while year-end leverage is expected at about 4.7x. “Free cash flow for the quarter was $461million and brings the year-to-date total to more than $600million.”

The portfolio shift is working, but demand is not yet broad. Engineered Materials’ adjusted EBIT rose 5% year over year, or about 9% excluding Micromax, as medical sales grew 16% and electronics sales 30%; those higher-value markets helped offset automotive weakness, lower volumes, inflation, and logistics costs. Acetyl Chain adjusted EBIT increased more than 25%, but management expects both segments to moderate sequentially in the fourth quarter because of seasonality and continued soft demand conditions.

The outlook improves cash generation more than near-term growth visibility. EPS guidance of $6.00–$6.25 remains intact, while the raised cash-flow range and planned $152 million Nutrinova proceeds strengthen debt repayment capacity. The remaining issue is execution: the company still carries 4.9x net debt-to-operating EBITDA and expects $20 million of fourth-quarter inventory absorption tied to nylon optimization.

Bottom line: Celanese delivered an earnings beat and a meaningful cash-flow upgrade, strengthening the turnaround and deleveraging story. But the revenue miss and falling volumes keep this from being a clean acceleration signal; the improvement is real, yet still driven more by mix, pricing, and execution than by broad demand recovery.

What to watch next

December investor strategy and technology update

Original filing on SEC EDGAR

More Celanese Corp news

Celanese earnings beat EPS, but revenue misses and cash flow rises | CE Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.